Research Overview of Novorapid Insulin Analogue
Novorapid Novo Nordisk is a fast-acting recombinant human insulin analogue manufactured by Novo Nordisk for in-vitro research applications. This insulin aspart formulation represents a genetically modified human insulin where proline at position B28 is substituted with aspartic acid, resulting in reduced self-association and faster absorption kinetics compared to regular human insulin in experimental models. Researchers at Stroid UK Shop utilise this compound to investigate glucose metabolism pathways, insulin receptor binding affinity studies, and cellular uptake mechanisms in controlled laboratory environments.
The rapid-acting properties of this insulin aspart formulation make it particularly valuable for researchers studying postprandial glucose responses and time-sensitive metabolic processes. Unlike intermediate or long-acting insulin preparations available through our general health insulin research category, Novorapid demonstrates onset of action within 10-15 minutes in experimental models, with peak activity occurring between 1-3 hours post-administration in research protocols.
Laboratory Applications and Research Protocols
Research applications for Novorapid encompass diabetes mellitus pathophysiology studies, insulin resistance investigations, and glucose homeostasis research. Laboratory teams examine this compound’s effects on cellular glucose uptake, glycogen synthesis pathways, and lipid metabolism regulation in various experimental models. The rapid pharmacokinetic profile enables researchers to study acute insulin responses and short-term metabolic effects with precise temporal control. Studies investigating insulin signalling cascades, particularly the PI3K/Akt pathway and glucose transporter translocation, frequently employ this fast-acting formulation. Research groups also utilise Novorapid in comparative studies against other metabolic modulators found in our SARMs research collection to understand tissue-specific metabolic responses. Additionally, this insulin analogue serves as a reference standard in studies examining novel glucose-lowering compounds and investigating insulin sensitisation mechanisms in cellular models.
Product Specifications and Research Data
| Parameter | Specification |
|---|---|
| Active Ingredient | Insulin Aspart (rDNA origin) |
| Manufacturer | Novo Nordisk |
| Formulation Type | Injectable Solution |
| Onset Profile | Rapid-acting (10-15 minutes) |
| Peak Activity | 1-3 hours (research models) |
| Storage Temperature | 2-8°C (unopened) |
| Research Applications | Glucose metabolism, insulin signalling |
| CAS Number | Verify with supplier |
This pharmaceutical-grade insulin preparation undergoes rigorous quality control testing to ensure consistency in research applications. The formulation includes excipients such as glycerol, phenol, and zinc chloride to maintain stability and prevent bacterial growth during laboratory storage. Researchers studying insulin pharmacodynamics often compare this rapid-acting profile against peptide compounds available in our peptides research section to understand different mechanisms of metabolic regulation.
Compliance and Laboratory Use Declaration
This product is supplied exclusively for in-vitro laboratory research purposes and is not intended for human consumption, clinical use, or therapeutic applications. Researchers must maintain appropriate laboratory protocols, safety documentation, and waste disposal procedures when handling this insulin preparation. All studies should be conducted within approved research facilities with proper ethical oversight and institutional review board approval where applicable.
